Search

This document provides information about a clinical trial for a drug called AZD0486. The trial aims to assess the safety and efficacy of AZD0486 as a monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies. The trial will include three substudies focusing on different populations with specific types of lymphoma. The trial will evaluate the safety, tolerability, and preliminary efficacy of AZD0486 through various outcome measures. The document also provides a list of keywords related to medical research and discoveries, serving as a resource for library patrons conducting research on these topics. The document is provided by AstraZeneca and was verified in August 2024. [Extracted from the article]

This document provides information about a clinical trial, NCT06561425, that is currently recruiting participants to evaluate the feasibility, safety, and efficacy of an experimental treatment called GLPG5101 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). The trial aims to determine the optimal dose of GLPG5101 with the fewest side effects in the first phase, and in the second phase, all participants will receive the best dose identified. The trial will assess various outcome measures, including adverse events, objective response, duration of response, and survival rates. The trial is open to individuals with aggressive DLBCL, FL, MZL, MCL, BL, PCNSL, relapsed or refractory disease, and adequate bone marrow, renal, hepatic, and pulmonary function. The trial is being conducted in the United States, Belgium, and the Netherlands, and contact information for further inquiries is provided. [Extracted from the article]

Researchers at the Beckman Research Institute in Monrovia, California have made new findings regarding chronic lymphocytic leukemia (CLL) and its progression to aggressive lymphoma, known as Richter's transformation (RT). The study focused on the role of MGA (Max gene associated) in CLL and RT, and found that MGA deletion leads to RT by modulating mitochondrial oxidative phosphorylation (OXPHOS). The researchers identified Nme1 as an MGA target that drives RT by modulating OXPHOS, and suggested that concurrent inhibition of MYC and electron transport chain complex II could potentially prolong the survival of RT mice. This research provides insights into potential therapeutic avenues for RT. [Extracted from the article]

A study conducted by researchers at Titu Maiorescu University in Bucharest, Romania, has investigated the role of the P53 gene and P53 protein in non-Hodgkin malignant lymphoma. The study focused on the impact of P53 gene mutations on the clinical course of chronic lymphocytic leukemia (CLL) and the relationship between P53 protein expression and disease stage, treatment response, and survival. The researchers used the Enzyme-Linked Immune-Absorbent Assay (ELISA) technique to analyze the frequency of P53 protein expression in 85 CLL patients. The findings of this study contribute to a better understanding of the genetic abnormalities associated with cancer and their implications for patient outcomes. [Extracted from the article]

A recent study conducted at Cheikh Anta Diop University in Dakar, Senegal, focused on a case of Hodgkin variant Richter syndrome (HvRS) in a patient with lymphocytic lymphoma. The 63-year-old patient presented with symptoms such as night sweats, weight loss, and persistent pruritus, along with an abdominal mass. The diagnosis was challenging due to limited resources and a shortage of haematopathologists in the region. This case highlights the difficulties in diagnosing HvRS in Sub-Saharan Africa and emphasizes the need for improved diagnostic capabilities in the region. [Extracted from the article]

A recent report from the University Hospital Center Clermont-Ferrand discusses the use of blinatumomab, a monoclonal antibody, as a treatment for Richter transformation (RT), an aggressive lymphoma that occurs in patients with chronic lymphocytic leukemia. The study found that blinatumomab demonstrated promising anti-tumor activity and acceptable toxicity in patients with RT. The primary endpoint of the trial, the complete response rate after blinatumomab induction, was met, and the overall response rate was 46%. Common adverse events included fever, anemia, and lymphopenia. Further research and clinical trials are needed to explore the potential of blinatumomab as a treatment option for RT. [Extracted from the article]

The article offers information on the challenges in diagnosing accelerated chronic lymphocytic leukemia/small lymphocytic lymphoma (aCLL/SLL) and Richter transformation. Topics discussed include the variability among pathologists in diagnosing aCLL/SLL and Richter transformation; the role of immunohistochemical markers in this assessment; and the need for further studies to refine diagnostic indicators for aggressive disease forms.

The article discusses a study on the efficacy, safety, tolerability, and pharmacokinetics of DZD8586 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, conducted by Dizal Pharmaceuticals, published in the journal Clinical Trials Week on August 20, 2024. Topics include the study's focus on the anti-tumor activity of DZD8586 as monotherapy, the evaluation of side effects, and the measurement of drug levels in the body.

The document provides information about a clinical trial for the treatment of Chronic Lymphocytic Leukemia (CLL). The trial, called NCT06524375 or BRAVE, aims to evaluate the effectiveness of adding the drug Venetoclax to commercially prescribed cBTKi in patients with CLL. The goal of the study is to achieve deep durable remissions with undetectable measurable residual disease by the end of combination treatment. The trial is not yet recruiting and plans to enroll 100 participants. It is being conducted by Genentech, Inc. and more information can be obtained from the provided contact details. [Extracted from the article]

A recent study conducted by researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, has provided new insights into Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). The study focused on the clonal expansion of B-cells, which is a key factor in the development of CLL and RS. Through high-throughput sequencing and single-cell studies, the researchers were able to create a molecular map of these diseases, shedding light on their biology and potential treatment options. The study also highlighted the need for further research to address remaining questions about the origin of the B-cell clone, the role of the tumor microenvironment, and therapeutic resistance mechanisms. This research has the potential to improve patient care and treatment outcomes. [Extracted from the article]

A new study conducted by researchers at the University Clinical Centre Ljubljana explores chronic lymphocytic leukemia (CLL), the most prevalent type of leukemia in Western populations. The study highlights the heterogeneity of factors contributing to CLL development at multiple levels, hindering research into potential treatment options. The researchers aggregated and presented important aspects of various omics levels of the disease, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and more. Multi-omics studies, which integrate different layers of data, have shown promising results and may assist clinicians in making improved treatment choices based on CLL subtypes and identifying novel biomarkers and targets for treatments. [Extracted from the article]

A recent study from Zhejiang, People's Republic of China, explores a rare case of Richter transformation (RT) with breast involvement as the first symptom. RT is the development of intrusive lymphoma in individuals previously or concurrently diagnosed with chronic lymphocytic leukemia (CLL). The case report describes an elderly female patient who presented with breast lesions and was later diagnosed with CLL and diffuse large B-cell lymphoma. The patient's treatment involved zanubrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The study also includes a comprehensive literature review on RT, its prognosis implications, therapeutic approaches, and emerging directions in treatment modalities. [Extracted from the article]

A recent study conducted at Paracelsus Medical University in Salzburg, Austria, has found that resistance to the drug ibrutinib in patients with chronic lymphocytic leukemia (CLL) can be attributed to abnormal signaling in the mammalian target of rapamycin (MTOR) pathway. The researchers suggest that combining MTOR inhibitors with ibrutinib could be a potential strategy to overcome therapy resistance in CLL patients. This study provides valuable insights into the development of novel treatment combinations to increase the efficacy of CLL treatment. [Extracted from the article]

A recent report discusses research on Richter's syndrome, a type of lymphoma. The study focuses on diffuse large B-cell lymphoma (DLBCL), which is the most common type of lymphoid malignancy and has various subtypes. The researchers highlight the importance of the TP53 gene, which is mutated or deleted in 20-30% of DLBCL cases, as a prognostic factor for patients. They suggest that TP53 mutational status could be used for risk stratification and treatment decisions in DLBCL. The study emphasizes the need for improved risk-stratification models for DLBCL patients. [Extracted from the article]

Researchers from the University of Texas MD Anderson Cancer Center have published a report on chronic lymphocytic leukemia (CLL) and Richter transformation (RT). CLL is a type of cancer that often does not respond to treatment or relapses, and in some cases, it transforms into a diffuse large B-cell lymphoma (DLBCL) known as Richter transformation. The researchers highlight the importance of understanding the biology of CLL and RT in order to develop effective therapeutic strategies. They discuss the use of mouse models to study the progression and transformation of the disease and how these models can contribute to the development of innovative treatments. [Extracted from the article]

A patent application has been submitted for a new treatment method for Richter's syndrome, a type of aggressive lymphoma that can develop in patients with chronic lymphocytic leukemia (CLL). The treatment involves the use of a bispecific antibody called epcoritamab, which targets two proteins, CD3 and CD20. The antibody would be administered to patients at varying doses and schedules, with the goal of achieving a complete response, partial response, or stable disease. The application also mentions the use of prophylaxis for certain side effects and supportive therapy. The treatment has shown effectiveness in patients who have previously received therapies for Richter's syndrome. [Extracted from the article]

A recent study conducted at University Hospital Basel in Switzerland reported a rare case of a patient with chronic lymphocytic leukemia (CLL) who developed an aggressive form of lymphoma known as Burkitt lymphoma. The patient initially presented with localized swelling in the neck and was found to have monoclonal B-cell lymphocytosis with a CLL immunophenotype. Further analysis revealed the presence of Burkitt lymphoma in the submandibular gland and adjacent lymph node. The patient was treated with DA-EPOCH-R and achieved a complete metabolic response. This case highlights the atypical transformation of CLL into Burkitt lymphoma in a treatment-naive patient. [Extracted from the article]

This document provides information about a clinical trial, NCT06428019, that aims to evaluate the safety and effectiveness of different drug combinations for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The trial will involve approximately 120 adult participants with CLL at 80 sites worldwide. The study will assess adverse events, changes in disease activity, and the effects of oral venetoclax in combination with either intravenously infused obinutuzumab or oral acalabrutinib. Regular visits, medical assessments, blood tests, and questionnaires will be conducted to monitor the treatment's effects. The trial is expected to be completed by October 2026, and data sharing is planned. [Extracted from the article]

A recent study conducted by researchers at the University of Brescia in Italy examined the use of 2-[18F]FDG PET/CT in identifying Richter transformation (RT) in chronic lymphocytic leukemia (CLL). RT is a rare phenomenon where CLL cells transform into a more aggressive lymphoma variant. The study analyzed 15 published studies on this topic, involving 1593 CLL patients. The researchers found that 2-[18F]FDG PET/CT showed promise as a non-invasive tool for early identification of CLLs at high risk of RT, with a sensitivity of 86.8% and a specificity of 48.1% using a cut-off value of five. However, further investigation is needed on other metabolic features. [Extracted from the article]

The patent application titled "Methods Of Treating B-Cell Proliferative Disorder" discusses a method of treating B-cell proliferative disorders, such as chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), using a drug called zanubrutinib. The inventors propose administering zanubrutinib along with a moderate CYP3A inducer to extend progression-free survival and reduce side effects. The application includes specific dosing recommendations and eligibility criteria for patients. It also addresses the assessment and treatment of tumor lysis syndrome (TLS) during treatment. For more detailed information and claims, readers can refer to the patent application. [Extracted from the article]

A recent report published by the International Atomic Energy Agency (IAEA) discusses the use of PET/CT imaging in the detection and evaluation of leukemia. The study highlights the effectiveness of 2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) in assessing hematologic malignancies, particularly lymphoma. The researchers emphasize that [18F]FDG PET/CT provides a comprehensive assessment of the entire bone marrow, complementing the limited information obtained from biopsy samples. The study also explores the potential of novel PET/CT radiotracers in specific scenarios for leukemia patients. Overall, the report aims to provide an overview of the current applications of [18F]FDG PET/CT in staging and monitoring leukemia patients, as well as the potential for its expanding role in the future. [Extracted from the article]

A recent report from the University of Illinois discusses the rare occurrence of Richter's syndrome (RS), which is when a patient with chronic lymphocytic leukemia (CLL) develops an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL). The report focuses on a 61-year-old woman with relapsed/refractory CLL who presented with subcutaneous nodules on her arms and legs and a dermal plaque on her abdomen. Skin biopsy confirmed a diagnosis of DLBCL, ABC-type, and her condition rapidly worsened following the diagnosis. The report emphasizes the importance of prompt skin biopsy in CLL patients with progressive skin lesions and aims to raise awareness of this aggressive clinical syndrome. [Extracted from the article]

A Phase I clinical trial, NCT06351527, has been launched to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of a drug called ICP-248 in patients with mature B-cell malignancies. The trial aims to determine the maximum tolerated dose and recommended Phase 2 dose of ICP-248 monotherapy, as well as investigate the incidence, nature, and severity of adverse events. The study is interventional, with a single group assignment, and is expected to enroll 40 participants. The trial is not yet recruiting, with an estimated completion date of October 25, 2027. [Extracted from the article]

A new study conducted by researchers at Ohio State University explores the use of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for Richter transformation (RT), a condition with poor outcomes using current therapies. The study involved a retrospective analysis of 69 patients who received CAR-T treatment for RT. The results showed that CAR-T demonstrated clinical efficacy, with an overall response rate of 63% and a median progression-free survival of 4.7 months. The study provides valuable insights into the potential of CAR-T therapy for patients with RT. [Extracted from the article]

A recent study conducted by Mayo Clinic researchers examined the use of venetoclax-based treatment for patients with Richter transformation (RT) of chronic lymphocytic leukemia (CLL). The study found that venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in some patients. However, patients with CLL and del(17p) or TP53 mutations had lower response rates and shorter progression-free survival. The study suggests that venetoclax may be a promising treatment option for RT patients, but further research is needed. [Extracted from the article]

A recent report from the Division of Regenerative Medicine discusses the treatment of Hodgkin lymphoma variant of Richter's transformation (HvRT), a rare complication for patients with chronic lymphocytic leukemia (CLL). The report presents a case series of four patients with HvRT who were treated with a combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). Two patients experienced durable remissions of 40 and 42 months, while the other two patients had disease progression and ultimately died. The researchers emphasize the need for further investigation into the optimal management of HvRT. [Extracted from the article]

Researchers from the Institute of Hematology and Transfusion Medicine in Warsaw, Poland have published a report on chronic lymphocytic leukemia (CLL). The report discusses the recent improvements in CLL management and the main strategies used to restrain CLL activity, such as targeting B-cell lymphoma (BCL-2) and Bruton's kinase (BTK). However, the report also highlights the challenges of resistance, adverse effects, and Richter's transformation that can lead to discontinuation of these therapies. The researchers explore the resistance mechanisms for both ibrutinib and venetoclax and present innovative approaches for treating double-refractory CLL. [Extracted from the article]

A recent study from the University of Western Australia explores the management of Richter transformation (RT), which refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. The study highlights that standard therapies have limited effectiveness, but recent advancements in understanding the biology of RT and the development of targeted therapies offer hope for improved outcomes. The review analyzes data on the pathogenesis and treatment of RT, including emerging therapies such as chimeric antigen receptor T-cell therapy, noncovalent Bruton tyrosine kinase inhibitors, and T-cell-engaging bispecific antibodies. The researchers emphasize the need for larger clinical trials to confirm the efficacy and safety of these novel agents. [Extracted from the article]

Researchers at Qingdao University have published new findings on Richter's syndrome, a condition where chronic lymphocytic leukemia transforms into high-grade lymphoma. The study focuses on a rare case of extranodal Richter's syndrome involving the heart, which is associated with a low response to chemotherapy and a poor prognosis. The researchers present the case of a 64-year-old woman with aggressive diffuse large B-cell lymphoma in the heart, providing insights into the diagnosis of cardiac lymphoma. The study was published in BMC Cardiovascular Disorders and can be accessed for free. [Extracted from the article]

A report from Saga University in Japan discusses the use of programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade in the treatment of lymphomas. While PD-1/PD-L1 blockade has shown promising results for classic Hodgkin lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL), its effectiveness in other lymphoma subtypes has been limited. The report reviews current combination therapies involving PD-1/PD-L1 blockade for lymphoma and explores potential therapeutic approaches. Clinical trials are ongoing to investigate appropriate combination regimens for cHL, chronic lymphocytic leukemia (CLL) with Richter transformation, and T-cell lymphoma. [Extracted from the article]

A study conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle, Washington, explored the factors associated with the long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). The study analyzed data from 47 patients with R/R CLL and/or Richter transformation who were treated with CD19 CAR T-cell therapy. The findings revealed that certain factors, such as maximum standardized uptake value and bulky disease before lymphodepletion, were associated with shorter progression-free survival. On the other hand, factors like complete response by positron emission tomography-computed tomography, measurable residual disease negativity, and higher CAR T-cell expansion were associated with longer progression-free survival. The study concluded that CD19 CAR T-cell therapy can achieve durable responses with curative potential in some patients with R/R CLL. [Extracted from the article]

Houston, State:Texas, United States, North and Central America, Antineoplastics, BCL-2 Inhibitors, Drugs and Therapies, Ibrutinib Therapy, Kinase Inhibitors, Pharmaceuticals, Protein Kinase Inhibitors, Venetoclax Therapy Keywords: Houston; State:Texas; United States; North and Central America; Antineoplastics; BCL-2 Inhibitors; Drugs and Therapies; Ibrutinib Therapy; Kinase Inhibitors; Pharmaceuticals; Protein Kinase Inhibitors; Venetoclax Therapy EN Houston State:Texas United States North and Central America Antineoplastics BCL-2 Inhibitors Drugs and Therapies Ibrutinib Therapy Kinase Inhibitors Pharmaceuticals Protein Kinase Inhibitors Venetoclax Therapy 1200 1200 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies - Antineoplastics have been presented. [Extracted from the article]

Keywords: Alkylating Agents; Antimetabolites; Antineoplastics; B-Cell Lymphoma; Cancer; Central Nervous System; Chemotherapy; Clinical Research; Clinical Trials and Studies; Cyclophosphamide Therapy; Disease Attributes; Disease Attributes - Disease Progression; Disease Progression; Drugs and Therapies; Fludarabine Therapy; Genetics; Health and Medicine; Hematology; Immunoproliferative Disorders; Large B-Cell Lymphoma; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Oncology; Pharmaceuticals EN Alkylating Agents Antimetabolites Antineoplastics B-Cell Lymphoma Cancer Central Nervous System Chemotherapy Clinical Research Clinical Trials and Studies Cyclophosphamide Therapy Disease Attributes Disease Attributes - Disease Progression Disease Progression Drugs and Therapies Fludarabine Therapy Genetics Health and Medicine Hematology Immunoproliferative Disorders Large B-Cell Lymphoma Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Oncology Pharmaceuticals 40 40 1 10/30/23 20231030 NES 231030 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT06079164, which has the following summary description: "This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). [Extracted from the article]

For more information on this research see: Artificial Intelligence-assisted Mapping of Proliferation Centers Allows the Distinction of Accelerated Phase From Large Cell Transformation In Chronic Lymphocytic Leukemia. Keywords: Houston; State:Texas; United States; North and Central America; Artificial Intelligence; Cancer; Chronic Lymphocytic Leukemia; Emerging Technologies; Health and Medicine; Hematology; Immunoproliferative Disorders; Leukemia; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Machine Learning; Oncology EN Houston State:Texas United States North and Central America Artificial Intelligence Cancer Chronic Lymphocytic Leukemia Emerging Technologies Health and Medicine Hematology Immunoproliferative Disorders Leukemia Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Machine Learning Oncology 533 533 1 10/24/23 20231026 NES 231026 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Artificial Intelligence. [Extracted from the article]

Keywords: Cancer; Diagnostics and Screening; Follicular Lymphoma; Health and Medicine; Hematology; Immunoproliferative Disorders; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Oncology EN Cancer Diagnostics and Screening Follicular Lymphoma Health and Medicine Hematology Immunoproliferative Disorders Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Oncology 405 405 1 10/24/23 20231026 NES 231026 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in follicular lymphoma. Cancer, Diagnostics and Screening, Follicular Lymphoma, Health and Medicine, Hematology, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Oncology. [Extracted from the article]

Keywords for this news article include: Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Cancer, Oncology, Neoplasms, Health and Medicine, Chronic Lymphocytic Leukemia. Keywords: Cancer; Chronic Lymphocytic Leukemia; Health and Medicine; Leukemia; Neoplasms; Oncology EN Cancer Chronic Lymphocytic Leukemia Health and Medicine Leukemia Neoplasms Oncology 587 587 1 10/24/23 20231026 NES 231026 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on chronic lymphocytic leukemia. [Extracted from the article]

The development of Richter transformation under venetoclax treatment highlights an area that requires further investigation and consideration in the management of CLL. After 4 cycles of DA-R-EPOCH treatment, single-agent ibrutinib was started due to treatment-resistant disease and an ECOG performance score of 2. Keywords: Antineoplastic Monoclonal Antibodies; Antineoplastics; Antirheumatics; BCL-2 Inhibitors; Biotechnology; CD20 Monoclonal Antibodies; Cancer; Chronic Lymphocytic Leukemia; Drugs and Therapies; Health and Medicine; Hematology; Immunologic Agents; Immunoproliferative Disorders; Leukemia; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Medical Devices; Monoclonal Antibodies; Oncology; Pharmaceuticals; Rituximab Therapy; Tyrosine Kinase Inhibitors; Venetoclax Therapy EN Antineoplastic Monoclonal Antibodies Antineoplastics Antirheumatics BCL-2 Inhibitors Biotechnology CD20 Monoclonal Antibodies Cancer Chronic Lymphocytic Leukemia Drugs and Therapies Health and Medicine Hematology Immunologic Agents Immunoproliferative Disorders Leukemia Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Medical Devices Monoclonal Antibodies Oncology Pharmaceuticals Rituximab Therapy Tyrosine Kinase Inhibitors Venetoclax Therapy 448 448 1 10/24/23 20231024 NES 231024 2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in chronic lymphocytic leukemia. [Extracted from the article]

By devising a TIGIT/CD226 ratio, we showed that CLL cells favoring TIGIT over CD226 are typical of a more indolent disease, while those favoring CD226 are characterized by a shorter time to first treatment and shorter progression-free survival after first treatment. Keywords: Turin; Italy; Europe; Cancer; Chronic Lymphocytic Leukemia; Health and Medicine; Hematology; Leukemia; Lymphocytic Leukemia; Oncology EN Turin Italy Europe Cancer Chronic Lymphocytic Leukemia Health and Medicine Hematology Leukemia Lymphocytic Leukemia Oncology 366 366 1 09/19/23 20230918 NES 230918 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Chronic Lymphocytic Leukemia. [Extracted from the article]

Relapsed disease is defined when a patient progressed (3 months) after achieving CR with a previous treatment Refractory disease is defined when a patient failed to achieve a CR or PR after a previous treatment Patients received at least 1 prior therapy for PTCL. Patients with HIV can be included if they are on appropriate antiretroviral therapy, there is no interaction with the study drug, a CD4+ T-cell counts ≥ 350 cells/L and no detectable viral load. [Extracted from the article]

Keywords: New York City; State:New York; United States; North and Central America; Cancer; Chronic Lymphocytic Leukemia; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine; Hematology; Immunoproliferative Disorders; Leukemia; Lymphatic Diseases and Conditions; Lymphocytic Lymphoma; Lymphoma; Lymphoproliferative Disorders; Oncology; Pharmaceuticals; Small Lymphocytic Lymphoma EN New York City State:New York United States North and Central America Cancer Chronic Lymphocytic Leukemia Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine Hematology Immunoproliferative Disorders Leukemia Lymphatic Diseases and Conditions Lymphocytic Lymphoma Lymphoma Lymphoproliferative Disorders Oncology Pharmaceuticals Small Lymphocytic Lymphoma 390 390 1 08/07/23 20230807 NES 230807 2023 AUG 7 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Small Lymphocytic Lymphoma. For more information on this research see: Current Treatment Options In Relapsed and Refractory Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma: a Review. [Extracted from the article]

Keywords: Rochester; State:Minnesota; United States; North and Central America; Cancer; Chronic Lymphocytic Leukemia; Health and Medicine; Hematology; Leukemia; Lymphocytic Leukemia; Oncology; Risk and Prevention EN Rochester State:Minnesota United States North and Central America Cancer Chronic Lymphocytic Leukemia Health and Medicine Hematology Leukemia Lymphocytic Leukemia Oncology Risk and Prevention 2104 2104 1 07/10/23 20230711 NES 230711 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Oncology - Chronic Lymphocytic Leukemia is the subject of a report. Richter transformation (RT), or the development of an aggressive lymphoma from a background of CLL, is a well-recognized complication of CLL and carries significantly poor clinical outcomes.". [Extracted from the article]

Keywords: Cancer; Chronic Lymphocytic Leukemia; Clinical Research; Clinical Trials and Studies; Health and Medicine; Hematology; Leukemia; Lymphocytic Leukemia; Oncology; Oncology - Chronic Lymphocytic Leukemia EN Cancer Chronic Lymphocytic Leukemia Clinical Research Clinical Trials and Studies Health and Medicine Hematology Leukemia Lymphocytic Leukemia Oncology Oncology - Chronic Lymphocytic Leukemia 391 391 1 06/12/23 20230612 NES 230612 2023 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT05879133, which has the following summary description: "To learn if exercise and weight management can help to improve feelings of fatigue in CLL survivors." Cancer, Chronic Lymphocytic Leukemia, Clinical Research, Clinical Trials and Studies, Health and Medicine, Hematology, Leukemia, Lymphocytic Leukemia, Oncology, Oncology - Chronic Lymphocytic Leukemia. [Extracted from the article]

Keywords for this news article include: Houston, Texas, United States, North and Central America, Antineoplastics, BCL-2 Inhibitors, Bone Marrow, Drugs and Therapies, Health and Medicine, Ibrutinib Therapy, Kinase Inhibitors, Pharmaceuticals, Protein Kinase Inhibitors, Venetoclax Therapy, University of Texas MD Anderson Cancer Center. Keywords: Houston; State:Texas; United States; North and Central America; Antineoplastics; BCL-2 Inhibitors; Bone Marrow; Drugs and Therapies; Health and Medicine; Ibrutinib Therapy; Kinase Inhibitors; Pharmaceuticals; Protein Kinase Inhibitors; Venetoclax Therapy EN Houston State:Texas United States North and Central America Antineoplastics BCL-2 Inhibitors Bone Marrow Drugs and Therapies Health and Medicine Ibrutinib Therapy Kinase Inhibitors Pharmaceuticals Protein Kinase Inhibitors Venetoclax Therapy 633 633 1 06/05/23 20230609 NES 230609 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Drugs and Therapies - Antineoplastics. [Extracted from the article]

If cytopenias are due to disease in the bone marrow any degree of anemia or thrombocytopenia are allowed Hemoglobin = 7 g/dL (independent of growth factor support or infusion support at screening unless evidence shows that the cytopenia[s] is due to marrow involvement by CLL/SLL). If cytopenias are due to disease in the bone marrow any degree of anemia or thrombocytopenia are allowed, ANC must be = 500 Platelets = 30,000/mm^3 (independent of growth factor support or infusion support at screening unless evidence shows that the cytopenia[s] is due to marrow involvement by CLL/SLL). [Extracted from the article]

For more information on this research see: Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. Keywords: Antigen Receptors; Blood Cells; Cancer; Chronic Lymphocytic Leukemia; Health and Medicine; Hematology; Hemic and Immune Systems; Immunologic Receptors; Immunology; Leukemia; Leukocytes; Lymphocytes; Lymphocytic Leukemia; Membrane Proteins; Natural Killer Cells; Oncology; Stem Cell Research EN Antigen Receptors Blood Cells Cancer Chronic Lymphocytic Leukemia Health and Medicine Hematology Hemic and Immune Systems Immunologic Receptors Immunology Leukemia Leukocytes Lymphocytes Lymphocytic Leukemia Membrane Proteins Natural Killer Cells Oncology Stem Cell Research 629 629 1 04/10/23 20230413 NES 230413 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Data detailed on chronic lymphocytic leukemia have been presented. [Extracted from the article]

An "immune evasion phenotype" (IEP) was defined as RT-DLBCL cases having high-positive expression of PD-1 and/or PD-L1 on tumor cells. Keywords: Houston; State:Texas; United States; North and Central America; B-Cell Lymphoma; Cancer; Drugs and Therapies; Genetics; Health and Medicine; Hematology; Immunoproliferative Disorders; Large B-Cell Lymphoma; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Oncology; Pharmaceuticals EN Houston State:Texas United States North and Central America B-Cell Lymphoma Cancer Drugs and Therapies Genetics Health and Medicine Hematology Immunoproliferative Disorders Large B-Cell Lymphoma Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Oncology Pharmaceuticals 1253 1253 1 04/10/23 20230413 NES 230413 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Fresh data on Oncology - B-Cell Lymphoma are presented in a new report. [Extracted from the article]

Keywords: Cancer; Chronic Lymphocytic Leukemia; Diagnostics and Screening; Health and Medicine; Hematology; Immunoproliferative Disorders; Leukemia; Lymphatic Diseases and Conditions; Lymphocytic Leukemia; Lymphoma; Lymphoproliferative Disorders; Oncology EN Cancer Chronic Lymphocytic Leukemia Diagnostics and Screening Health and Medicine Hematology Immunoproliferative Disorders Leukemia Lymphatic Diseases and Conditions Lymphocytic Leukemia Lymphoma Lymphoproliferative Disorders Oncology 641 641 1 04/03/23 20230404 NES 230404 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in chronic lymphocytic leukemia. According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "Richter Transformation (RT) refers to the development of an aggressive lymphoma in the setting of chronic lymphocytic leukemia (CLL).". [Extracted from the article]

According to news originating from Barcelona, Spain, by NewsRx correspondents, research stated, "Fludarabine-cyclophosphamide-rituximab (FCR) has been the gold standard front-line treatment for fit CLL patients until novel agent's introduction. Keywords: Barcelona; Spain; Europe; Alkylating Agents; Antimetabolites; Antineoplastic Monoclonal Antibodies; Antineoplastics; Antirheumatics; Biotechnology; CD20 Monoclonal Antibodies; Cancer; Chronic Lymphocytic Leukemia; Cyclophosphamide; Cyclophosphamide Therapy; Drugs and Therapies; Fludarabine Therapy; Health and Medicine; Hematology; Hydrocarbons; Immunologic Agents; Leukemia; Lymphocytic Leukemia; Medical Devices; Monoclonal Antibodies; Mustard Compounds; Oncology; Organophosphorus Compounds; Pharmaceuticals; Phosphoramide Mustards; Rituximab Therapy; Tyrosine Kinase Inhibitors EN Barcelona Spain Europe Alkylating Agents Antimetabolites Antineoplastic Monoclonal Antibodies Antineoplastics Antirheumatics Biotechnology CD20 Monoclonal Antibodies Cancer Chronic Lymphocytic Leukemia Cyclophosphamide Cyclophosphamide Therapy Drugs and Therapies Fludarabine Therapy Health and Medicine Hematology Hydrocarbons Immunologic Agents Leukemia Lymphocytic Leukemia Medical Devices Monoclonal Antibodies Mustard Compounds Oncology Organophosphorus Compounds Pharmaceuticals Phosphoramide Mustards Rituximab Therapy Tyrosine Kinase Inhibitors 1194 1194 1 03/24/23 20230228 NES 230228 2023 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Oncology - Chronic Lymphocytic Leukemia are presented in a new report. [Extracted from the article]